The Editor's Roundtable: Contrast-Induced Nephropathy

American Journal of Cardiology

Volumn 100, Issue 3, 2007, Pages 544-551

  Friedewald, Vincent E ^a   Goldfarb, Stanley ^b   Laskey, Warren K ^c   McCullough, Peter A ^d   Roberts, William C ^e  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; FUROSEMIDE;

ARTICLE; CONTRAST ENHANCEMENT; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; PRIORITY JOURNAL; VASODILATATION;

EID: 34547127382     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.05.021     Document Type: Note

References (6)

1. McCullough P.A., Adam A., Becker C.R., Davidson C., Lameire N., Stacul F., and Tumlin J. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 98 (2006) 5K-13K
2. McCullough P.A., Adam A., Becker C.R., Davidson C., Lameire N., Stacul F., and Tumlin J. Risk prediction of contrast-induced nephropathy. Am J Cardiol 98 (2006) 27K-36K
3. Hou S.H., Bushinsky D.A., Wish J.B., Cohen J.J., and Harrington J.T. Hospital-acquired renal insufficiency: a prospective study. Am J Med 74 (1983) 243-248
4. Nash K., Hafez A., and Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 39 (2002) 930-936
5. Laskey W, ed. Contrast-induced nephropathy. clinical insights and practical guidance. A report from the CIN consensus working panel. Am J Cardiol 2006;98(suppl):1K-77K.
6. FDA ALERT [06/2006]: Development of serious and sometimes fatal nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/gccaHCP.htm. Accessed May 1, 2007.